Sanofi Pasteur, the vaccines business of the sanofi-aventis Group, has made available Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) in the US for protection against tetanus, diphtheria, and pertussis from adolescence through adulthood.

Adacel vaccine is the first booster to address pertussis (whooping cough) protection across a wide range of ages (11 through 64 years) and the first and only such booster licensed for adults in the US. It was licensed by the US Food and Drug Administration (FDA) on June 10, 2005. It has been a licensed product in Canada and Germany.

Adacel vaccine should be administered as a single, 0.5 mL dose by intramuscular injection. It is sold in packages of ten, single-dose vials.